Table 7.6a

Immunosuppression Use for Induction, 1997 to 2006

Recipients with Pancreas After Kidney (PAK) Transplants

  Year of Transplant
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Transplants 130 156 220 304 305 375 344 420 343 293
With Immunosuppression Info 129 152 217 298 303 372 336 408 336 281
Induction Drugs 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 48.1% 19.7% 8.3% 1.7% 0.3% 2.4% 0.6% 1.5% 3.3% 0.0%
OKT3 24.8% 15.8% 8.8% 3.0% 0.7% 1.3% 0.9% 0.2% 0.0% 0.7%
Thymoglobulin 0.0% 0.7% 30.0% 37.2% 50.5% 51.9% 50.9% 57.4% 53.9% 56.2%
Zenapax 0.0% 26.3% 36.9% 32.6% 33.3% 25.3% 9.5% 6.6% 6.8% 2.5%
Simulect 0.8% 9.9% 10.6% 17.1% 13.2% 8.3% 8.0% 5.4% 2.7% 6.8%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 13.4% 19.1% 18.5% 13.5%
No Induction Drugs Recorded 26.4% 36.2% 33.6% 33.2% 25.1% 27.2% 25.9% 20.1% 21.7% 21.7%


Source: OPTN/SRTR Data as of May 1, 2007.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.